Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR84 | Q9NQS5 | 1/20 | 0.69 |
| ▸ | AHR | P35869 | 7/20 | 0.50 |
| ▸ | CSNK2A1 | P68400 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | CYP2A6 | P11509 | 3/20 | 0.41 |
| ▸ | NR4A2 | P43354 | 2/20 | 0.41 |
| ▸ | CMA1 | P23946 | 1/20 | 0.41 |
| ▸ | F7 | P08709 | 1/20 | 0.41 |
| ▸ | LTA4H | P09960 | 1/20 | 0.41 |
| ▸ | F3 | P13726 | 1/20 | 0.41 |
| ▸ | TYR | P14679 | 1/20 | 0.41 |
| ▸ | USP2 | O75604 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.41 |
| ▸ | RAD51 | Q06609 | 1/20 | 0.41 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.41 |
| ▸ | IMPDH2 | P12268 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL187774 | 0.92 | GPR84 (0.69) | GPR84AHRCSNK2A1MEN1POLB | |
| SCHEMBL30370306 | 0.92 | GPR84 (0.69) | GPR84AHRCSNK2A1MEN1POLB | |
| SCHEMBL10322228 | 0.86 | GPR84 (0.62) | GPR84AHRCSNK2A1MEN1POLB | |
| SCHEMBL188052 | 0.82 | GPR84 (1.00) | GPR84AHRCSNK2A1MEN1POLB | |
| SCHEMBL827047 | 0.82 | GPR84 (0.54) | GPR84AHRCSNK2A1MEN1POLB | |
| Tert-Butyl Formate SCHEMBL27584210 | 0.76 | GPR84 (0.49) | GPR84AHRCSNK2A1MEN1POLB | |
| SCHEMBL394578 | 0.75 | GPR84 (0.69) | GPR84AHRCSNK2A1MEN1POLB | |
| SCHEMBL849501 | 0.75 | CSNK2A1 (0.60) | GPR84AHRCSNK2A1MEN1POLB | |
| SCHEMBL8648526 | 0.75 | ALOX15 (0.50) | GPR84AHRCSNK2A1MEN1POLB | |
| SCHEMBL2986160 | 0.75 | GPR84 (0.47) | GPR84AHRCSNK2A1MEN1POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 92 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11820766-B2 | Monoacylglycerol lipase modulators | JANSSEN PHARMACEUTICA NV (BE) | 2023-11-21 | — | — | US | disclosed |
| US-20220332713-A1 | Monoacylglycerol Lipase Modulators | JANSSEN PHARMACEUTICA NV (BE) | 2022-10-20 | — | — | US | disclosed |
| WO-2022174253-A1 | HPK1 ANTAGONISTS AND USES THEREOF | Nimbus Saturn, Inc. (US) | 2022-08-18 | — | — | WO | disclosed |
| EP-3244886-B1 | INDOLE DERIVATIVES AS DENGUE VIRAL REPLICATION INHIBITORS | JANSSEN PHARMACEUTICALS INC (US) | 2021-10-27 | — | — | EP | disclosed |
| EP-3244886-B1 | INDOLE DERIVATIVES AS DENGUE VIRAL REPLICATION INHIBITORS | JANSSEN PHARMACEUTICALS INC (US) | 2021-10-27 | — | — | EP | disclosed |
| WO-2021067805-A1 | OXALAMIDE HETEROBYCYCLIC COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH STING ACTIVITY | IFM DUE, INC. (US) | 2021-04-08 | — | — | WO | disclosed |
| US-10857123-B2 | NLRP3 inhibitors for the treatment of inflammatory skin disorders | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2020-12-08 | — | — | US | disclosed |
| EP-3705477-A1 | MODULATORS OF ATP-BINDING CASSETTE TRANSPORTERS | Vertex Pharmaceuticals Incorporated (US) | 2020-09-09 | — | — | EP | disclosed |
| WO-2020065613-A1 | MONOACYLGLYCEROL LIPASE MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2020-04-02 | — | — | WO | disclosed |
| US-10398679-B2 | Treatment method utilizing pyrrolidine-2, 5-dione derivatives as IDO1 inhibitors | ITEOS THERAPEUTICS (BE) | 2019-09-03 | — | — | US | disclosed |
| US-20120184574-A1 | INDOLE DERIVATIVES AND METHODS FOR ANTIVIRAL TREATMENT | PTC THERAPEUTICS, INC. (US) | 2012-07-19 | — | — | US | disclosed |
| US-20120184574-A1 | INDOLE DERIVATIVES AND METHODS FOR ANTIVIRAL TREATMENT | PTC THERAPEUTICS, INC. (US) | 2012-07-19 | — | — | US | disclosed |
| EP-2417122-A1 | INDOLE DERIVATIVES AND METHODS FOR ANTIVIRAL TREATMENT | PTC Therapeutics, Inc. (US) | 2012-02-15 | — | — | EP | disclosed |
| US-8101767-B2 | Modulators of ATP-binding cassette transporters | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-01-24 | — | — | US | disclosed |
| WO-2010117932-A1 | INDOLE DERIVATIVES AND METHODS FOR ANTIVIRAL TREATMENT | SCHERING CORPORATION (US) | 2010-10-14 | — | — | WO | disclosed |
| WO-2010117932-A1 | INDOLE DERIVATIVES AND METHODS FOR ANTIVIRAL TREATMENT | SCHERING CORPORATION (US) | 2010-10-14 | — | — | WO | disclosed |
| US-20090246820-A1 | COMPOUNDS USEFUL IN CFTR ASSAYS AND METHODS THEREWITH | VERTEX PHARMACEUTICALS INCORPORATED | 2009-10-01 | — | — | US | disclosed |
| US-20090227797-A1 | MODULATORS OF ATP-BINDING CASSETTE TRANSPORTERS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2009-09-10 | — | — | US | disclosed |
| US-7495103-B2 | Modulators of ATP-binding cassette transporters | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2009-02-24 | — | — | US | disclosed |
| US-20080071095-A1 | Cystic fibrosis transmembrane conductance | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2008-03-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220332713-A1 | Monoacylglycerol Lipase Modulators | MGLL, LPL, PNLIP | GPR84 162/4885AHR 3562/4885CSNK2A1 943/4885 |
| US-20090227797-A1 | MODULATORS OF ATP-BINDING CASSETTE TRANSPORTERS | CFTR, ABCB1, ABCC2 | GPR84 522/4885AHR 954/4885CSNK2A1 4180/4885 |
| US-20120184574-A1 | INDOLE DERIVATIVES AND METHODS FOR ANTIVIRAL TREATMENT | IDO1, IRF3, MAVS | GPR84 1891/4885AHR 474/4885CSNK2A1 586/4885 |
| US-10857123-B2 | NLRP3 inhibitors for the treatment of inflammatory skin disorders | NLRP3, NLRP1, PYCARD | GPR84 628/4885AHR 170/4885CSNK2A1 3322/4885 |
| US-20080071095-A1 | Cystic fibrosis transmembrane conductance | CFTR, ABCB1, ABCC1 | GPR84 370/4885AHR 1625/4885CSNK2A1 3946/4885 |
| US-10398679-B2 | Treatment method utilizing pyrrolidine-2, 5-dione derivatives as IDO1 inhibitors | IDO1, IDO2, NAT1 | GPR84 2785/4885AHR 140/4885CSNK2A1 2255/4885 |
| US-11820766-B2 | Monoacylglycerol lipase modulators | MGLL, LPL, PNLIP | GPR84 162/4885AHR 3562/4885CSNK2A1 943/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.